Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sylvant

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

- PMLiVE

J&J gets FDA green light for myeloma drug Darzalex

First-in-classtargeted immunotherapy wins US approval

- PMLiVE

FDA approves Janssen’s Yondelis

Provides additional treatment option for softtissue sarcoma

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Blue Latitude retains Janssen contract

Strategic marketing consultancy will continue tosupport the firm's EMEA brand teams

- PMLiVE

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients

- PMLiVE

Imbruvica filed as first-line leukaemia therapy

Study shows improved progression-free survival

- PMLiVE

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

- PMLiVE

FDA grants Tocagen’s glioblastoma drug orphan status

Puts the brain cancer gene therapy in-line for development incentives

- PMLiVE

J&J files three-monthly schizophrenia drug in Europe

Hopes to gain advantage over its competitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links